Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.

Abbate A, Van Tassell B, Bogin V, Markley R, Pevzner DV, Cremer PC, Meray IA, Privalov DV, Taylor A, Grishin SA, Egorova AN, Ponomar EG, Lavrovsky Y, Samsonov MY, New Collective Author

Open source

DOI: 10.1097/fjc.0000000000001635
Published: 2024 Dec 1
Container: Journal of cardiovascular pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1097/fjc.0000000000001635,
  title = {Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.},
  author = {Abbate A and Van Tassell B and Bogin V and Markley R and Pevzner DV and Cremer PC and Meray IA and Privalov DV and Taylor A and Grishin SA and Egorova AN and Ponomar EG and Lavrovsky Y and Samsonov MY and New Collective Author},
  year = {2024},
  journal = {Journal of cardiovascular pharmacology},
  doi = {10.1097/fjc.0000000000001635},
  url = {https://doi.org/10.1097/fjc.0000000000001635}
}

RIS

TY  - JOUR
TI  - Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.
AU  - Abbate A
AU  - Van Tassell B
AU  - Bogin V
AU  - Markley R
AU  - Pevzner DV
AU  - Cremer PC
AU  - Meray IA
AU  - Privalov DV
AU  - Taylor A
AU  - Grishin SA
AU  - Egorova AN
AU  - Ponomar EG
AU  - Lavrovsky Y
AU  - Samsonov MY
AU  - New Collective Author
PY  - 2024
JO  - Journal of cardiovascular pharmacology
DO  - 10.1097/fjc.0000000000001635
UR  - https://doi.org/10.1097/fjc.0000000000001635
ER  -

APA

A, A., B, V. T., V, B., R, M., DV, P., PC, C., IA, M., DV, P., A, T., SA, G., AN, E., EG, P., Y, L., MY, S., & Author, N. C. (2024). Interleukin-1 Blockade With RPH-104 (Goflikicept) in Patients With ST-Segment Elevation Myocardial Infarction: Secondary End Points From an International, Double-Blind, Randomized, Placebo-Controlled, Phase 2a Study.. Journal of cardiovascular pharmacology. https://doi.org/10.1097/fjc.0000000000001635

Source records

pubmed · retrieved 2026-09-26T15:25:02.474Z